ClinicalTrials.Veeva

Menu

Dose Ranging Study With LT, Monotherapy, PPAR

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Completed
Phase 3
Phase 2

Conditions

Diabetes Mellitus II

Treatments

Drug: Muraglitazar

Study type

Interventional

Funder types

Industry

Identifiers

NCT00240383
CV168-006

Details and patient eligibility

About

A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

    1. HbA1c > 7.0% and ≤ 10.0% obtained at the Screening visit.
    1. Men and women, 18-70 years of age Established Type 2 diabetes

Exclusion criteria

    1. Symptomatic Type 2 diabetes defined as marked polyuria and polydipsia with greater than 10% weight loss during the last three months.
    1. Administration of antihyperglycemic agents (other than thiazolidinediones) for more than three consecutive or a total of seven non-consecutive days during the four weeks prior to screening.
    1. Administration of thiazolidinediones for more than three consecutive or a total of seven non-consecutive days during the six weeks prior to screening.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

272

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems